Acceptance & Commitment Therapy for Psychotic Inpatients

Acute Psychosis Clinical Trial

Official title:

Acceptance & Commitment Therapy for Psychotic Inpatients

Clinical Trial Details — Status: Withdrawn

Administrative data

• NCT number: NCT02458105
• Other study ID #: 2014/541
• Status: Withdrawn
• Phase: N/A
• Start date: April 2015
• Est. completion date: December 2017

Study information

• Verified date: May 2018
• Source: Uppsala University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The overarching aim of the research project is to investigate whether Acceptance & Commitment Therapy (ACT) is an efficacious psychotherapeutic method of treatment for inpatients suffering from acute psychosis.

The method will be applied in two ways. Firstly, as an individual treatment for patients. Secondly, as an integrated part of the daily work on an inpatient ward, administered by nurses and assistant nurses trained in the method.

Recruitment information / eligibility

• Status: Withdrawn
• Enrollment: 0
• Est. completion date: December 2017
• Est. primary completion date: December 2017
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Admitted to a specified psychiatric inpatient ward during the time-period of the study; psychotic spectrum diagnosis as specified in patient charts; assessed by contact person on the ward as having delusions or hallucinations.

Exclusion Criteria:

• Cognitive difficulties to an extent where informed consent cannot be given.

Related Conditions & MeSH terms

• Acute Psychosis

Intervention

Behavioral:
• Acceptance & Commitment Therapy
A variant of cognitive behavior therapy focused on acceptance and valued living in the presence of distressing symptoms.
• Attention
Supportive conversation at a frequency and length corresponding to the experimental condition.

Locations

Country	Name	City	State
Sweden	Västmanland Hospital, Västerås, Västmanland County Council	Västerås

Sponsors (2)

Lead Sponsor	Collaborator
Uppsala University	Stockholm University

Country where clinical trial is conducted

Sweden, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Rehospitalization	Whether or not, and if so for how many days, a patient has ben readmitted to inpatient care during the follow-up period.	12 months
Secondary	Bull's Eye Values Inventory	Quality of life instrument to be administered before treatment, after treatment, and at 3, 6 and 12 month follow-up.	12 months
Secondary	EQ-5D	Health related quality of life instrument to be administered before treatment, after treatment, and at 3, 6 and 12 month follow-up.	12 months
Secondary	Clinical Global Impression Scale	Symptom severity instrument to be administered before treatment, after treatment, and at 3, 6 and 12 month follow-up.	12 months
Secondary	Acceptance & Action Questionnaire	Psychological flexibility instrument to be administered before treatment, after treatment, and at 3, 6 and 12 month follow-up.	12 months
Secondary	Psychotic Symptom Rating Scales	Symptom severity instrument to be administered before treatment, after treatment, and at 3, 6 and 12 month follow-up.	12 months
Secondary	Checklist of Unit Behaviors	Measure for degree of activity on the ward.	During inpatient care.